Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study

Table 3 Responder analysis

	Anti-CGRP mAbs (n = 69)	BoNT-A (N = 85)	p-value	Adjusted OR (95%CI)	p-value
Responders at 12 months
50%, n (%)	49 (71.0)	33 (38.8)	< 0.001	8.6 (3.4 to 22.1)	< 0.001
75%, n (%)	24 (34.8)	9 (10.6)	< 0.001	8.3 (2.6 to 27.0)	< 0.001
100%, n (%)	2 (2.9)	0 (0.0)	0.199	NA	NA
Responders at 6 months
50%, n (%)	53 (76.8)	27 (31.8)	< 0.001	18.2 (6.4 to 52.1)	< 0.001
75%, n (%)	30 (43.5)	11 (12.9)	< 0.001	12.5 (3.8 to 41.1)	< 0.001
100%, n (%)	3 (4.4)	0 (0.0)	0.088	NA	NA

Responders were defined as patients achieving a reduction in MHD of 50%, 75%, and 100% at 6 and 12 months of follow-up compared to baseline
Responder analysis was performed on the population included in the primary outcome analysis
Abbreviations: 95%CI 95% confidence interval, BoNT-A Onabotulinumtoxin-A, CGRP Calcitonin gene related peptide, mAbs Monoclonal antibodies, MHD Monthly headache days, NA Not applicable, OR Odds ratio

ISSN: 1129-2377